Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)
Status:
Completed
Trial end date:
2020-10-15
Target enrollment:
Participant gender:
Summary
In order to understand the risks and benefits of edoxaban use in a real-world clinical
setting in the Non valvular Atrial Fibrillation (NVAF) indication, Daiichi-Sankyo proposed
this non-interventional study to gain insight into the safety (bleeding, liver adverse
events, all-cause mortality and other drug related adverse events) and efficacy of edoxaban
use in non-preselected patients with NVAF.